{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"LVJQJRUAYXVEGN-UHFFFAOYSA-N","prefName":"FAB-144","symbol":"FAB-144","iupacName":"[1-(5-fluoropentyl)indazol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone","aliases":["FAB-144"],"cas":null,"pubchemCid":"102135350","chebiId":null,"smiles":"CC1(C)C(C(=O)c2nn(CCCCCF)c3ccccc23)C1(C)C","molecularFormula":"C20H27FN2O","molecularWeight":330.4,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/102135350"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: FAB-144 is a synthetic compound, unrelated to the terpenophenols of hemp. It belongs to the class of indazole ketones, obtained by organic synthesis, described here by chemical class only.","originNote":"Entirely synthetic molecule, absent from cannabis. It is the indazole analogue of XLR-11 and the 5-fluoropentyl analogue of UR-144 (Hess et al., 2016): the indole of the skeleton is replaced by an indazole.","discovered":""},"pharmacology":{"summaryFr":"FAB-144 is an indazol-3-yl methanone, the indazole analogue of XLR-11 and the 5-fluoropentyl analogue of UR-144, and an agonist of the CB1 and CB2 cannabinoid receptors. Hess et al. (2016) describe an affinity slightly higher than that of UR-144 at both receptors, almost identical to that of XLR-11; the numerical values are given in their Table 1. The authors do not place it among the agonists with lower efficacy than THC. No human study, and no pharmacokinetic, metabolic or toxicological data specific to this molecule, has been identified, and no therapeutic use is established.","receptorSummaryFr":"CB1 and CB2 receptor agonist according to Hess et al. (2016), who measured its binding on membranes of CHO cells expressing the human receptors. Its affinity is described as slightly higher than that of UR-144 at both receptors, and almost identical to that of XLR-11. Tetramethylcyclopropyl derivatives of this group show a CB2 preference, whatever the side chain. The authors do not place it among the agonists with lower efficacy than THC.","binding":[{"target":"CB1","efficacy":"full_agonist","relativeActivity":80,"reported":"Ki 17,5 ± 1,1 nM (Hess et coll., 2016, tableau 1) ; affinité légèrement supérieure à celle de l'UR-144 dans le même article","confidence":"medium"},{"target":"CB2","efficacy":"full_agonist","relativeActivity":95,"reported":"Ki 0,450 ± 0,111 nM (Hess et coll., 2016, tableau 1) ; affinité légèrement supérieure à celle de l'UR-144, avec la préférence pour CB2 partagée par les dérivés tétraméthylcyclopropyle du groupe","confidence":"medium"}],"references":[{"label":"Hess C. et coll., Forensic Toxicology, 2016 : évaluation pharmacologique des cannabinoïdes de synthèse identifiés dans le spice","pmid":"27429655","doi":"10.1007/s11419-016-0320-2","url":"https://pubmed.ncbi.nlm.nih.gov/27429655/"},{"label":"ANSM · Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (rubrique indazol-3-yl méthanone)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"OICS · Liste verte des substances psychotropes sous contrôle international, édition 2026","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem · CID 102135350, FAB-144","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/102135350"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":6},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":3},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":5},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":4},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":8}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"No harmonised European Union control measure has been identified for this molecule in the sources consulted: control falls under national legislation.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"FAB-144 is not named in the consolidated ANSM list of 16 February 2026, but it falls under the generic definition of indazol-3-yl methanones, in the families block of the list (order of 22 February 1990, as amended). The nitrogen at position 1 of the indazole ring carries a haloalkyl substituent, 5-fluoropentyl, and the methanone bridge carbon carries a cyclopropyl group, here tetramethylated, which the definition allows whether substituted or not. Both conditions being met, the molecule is classed as a narcotic. Use, possession, transfer and importation are prohibited.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Hess C. et coll., Forensic Toxicology, 2016 : évaluation pharmacologique des cannabinoïdes de synthèse identifiés dans le spice","pmid":"27429655","doi":"10.1007/s11419-016-0320-2","url":"https://pubmed.ncbi.nlm.nih.gov/27429655/"},{"label":"ANSM · Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (rubrique indazol-3-yl méthanone)","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"OICS · Liste verte des substances psychotropes sous contrôle international, édition 2026","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"},{"label":"PubChem · CID 102135350, FAB-144","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/102135350"}],"meta":{"slug":"fab-144","url":"https://en.phytogrammes.com/wiki/fab-144","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}